As such, ocrelizumab-induced colitis is believed to be a consequence of B cell depletion, particularly Bregs, with subsequent reduction of IL-10 secretion, which leads to uninhibited Th1 cell activity and predisposes the patient to diminished anti-inflammatory responses (6–15, 25). This evidence concerns the gene IL10 and colitis.